Evaluating the Effectiveness of Small Fractionation Radiotherapy Regimens on the ACHN Renal Cell Carcinoma Cell Line

Document Type : Original Article (s)

Authors

1 Department of Medical Physics, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

2 Associate Professor, Department of Medical Genetics, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

3 Professor, Department of Medical Physics and Medical Engineering, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

4 Professor, Department of Medical Physics, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

5 Professor, Skin Disease and Leishmaniasis Research Center AND Department of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

6 Radiation Oncologist, Milad Hospital, Isfahan, Iran

Abstract

Background: Renal cell carcinoma is considered to be a radioresistant tumor. Consequently, radiotherapy is used mainly for palliation of metastases or local tumor growth. The aim of this study was to evaluate the efficacy of the radiation protocols with small fractions on cell killing of ACHN human renal cell carcinoma cell line.Methods: After cell culture, the ACHN cells were exposed to 6, 8 and 10 Gy of single fraction and 3 × 2, 4 × 2 and 5 × 2 Gy of two fractions. Viability was calculated using MTS assay [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium].Findings: Exposing cultured cells to small fractions of radiation resulted to a mean decrease of 70% in cell survival over 120 hours after radiation. Survival fraction reduced with increasing the dose per fraction. Two fractions 5 × 2 Gy showed significant effect on cell survival compared to single fraction 10 Gy (P = 0.02)Conclusion: Our results indicate that the small fraction is a valuable alternative to provide local tumor control.

Keywords

References

  1. Rathmell WK, Godley PA. Recent updates in renal cell carcinoma. Curr Opin Oncol 2010; 22(3): 250-6.
  2. United State Department of Health and Human Services, National Cancer Institute (NCI). Cancer incidence-Surveillance, Epidemiology, and End Results (SEER) Registries Research Data [Online]. [cited 2014]; Available from: URL: http://seer.cancer.gov/data/metadata.html
  3. Akbari ME, Hosseini SJ, Rezaee A, Hosseini MM, Rezaee I, Sheikhvatan M. Incidence of genitourinary cancers in the Islamic Republic of Iran: a survey in 2005. Asian Pac J Cancer Prev 2008; 9(4): 549-52.
  4. Bani-Hani AH, Leibovich BC, Lohse CM, Cheville JC, Zincke H, Blute ML. Associations with contralateral recurrence following nephrectomy for renal cell carcinoma using a cohort of 2,352 patients. J Urol 2005; 173(2): 391-4.
  5. Beitler JJ, Makara D, Silverman P, Lederman G. Definitive, high-dose-per-fraction, conformal, stereotactic external radiation for renal cell carcinoma. Am J Clin Oncol 2004; 27(6): 646-8.
  6. Graves A, Hessamodini H, Wong G, Lim WH. Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities. Immunotargets Ther 2013; 2: 73-90.
  7. Miyao N, Naito S, Ozono S, Shinohara N, Masumori N, Igarashi T, et al. Late recurrence of renal cell carcinoma: retrospective and collaborative study of the Japanese Society of Renal Cancer. Urology 2011; 77(2): 379-84.
  8. Svedman C, Karlsson K, Rutkowska E, Sandstrom P, Blomgren H, Lax I, et al. Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney. Acta Oncol 2008; 47(8): 1578-83.
  9. Bamias A, Tzannis K, Papatsoris A, Oudard S, Beuselinck B, Escudier B, et al. Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multiinstitutional study. Clin Genitourin Cancer 2014; 12(5): 373-83.
  10. Abara E, Chivulescu I, Clerk N, Cano P, Goth A. Recurrent renal cell cancer: 10 years or more after nephrectomy. Can Urol Assoc J 2010; 4(2): E45-E49.
  11. De MG, Khoo V, Escudier B, Joniau S, Bossi A, Ost P, et al. Radiotherapy for renal-cell carcinoma. Lancet Oncol 2014; 15(4): e170-e177.
  12. Fowler JF. Biological factors influencing optimum fractionation in radiation therapy. Acta Oncol 2001; 40(6): 712-7.
  13. Yang Y, Xing L. Optimization of radiotherapy dose-time fractionation with consideration of tumor specific biology. Med Phys 2005; 32(12): 3666-77.
  14. Wilson D, Hiller L, Gray L, Grainger M, Stirling A, James N. The effect of biological effective dose on time to symptom progression in metastatic renal cell carcinoma. Clin Oncol (R Coll Radiol) 2003; 15(7): 400-7.
  15. Miwa K, Matsuo M, Ogawa S, Shinoda J, Yokoyama K, Yamada J, et al. Re-irradiation of recurrent glioblastoma multiforme using 11C-methionine PET/CT/MRI image fusion for hypofractionated stereotactic radiotherapy by intensity modulated radiation therapy. Radiat Oncol 2014; 9: 181.
  16. Dunavoelgyi R, Dieckmann K, Gleiss A, Sacu S, Kircher K, Georgopoulos M, et al. Local tumor control, visual acuity, and survival after hypofractionated stereotactic photon radiotherapy of choroidal melanoma in 212 patients treated between 1997 and 2007. Int J Radiat Oncol Biol Phys 2011; 81(1): 199-205.
  17. Otsuka S, Shibamoto Y, Iwata H, Murata R, Sugie C, Ito M, et al. Compatibility of the linear-quadratic formalism and biologically effective dose concept to high-dose-per-fraction irradiation in a murine tumor. Int J Radiat Oncol Biol Phys 2011; 81(5): 1538-43.
  18. Marekova M, Vavrova J, Vokurkova D, Psutka J. Modulation of ionizing radiation-induced apoptosis and cell cycle arrest by all-trans retinoic acid in promyelocytic leukemia cells (HL-60). Physiol Res 2003; 52(5): 599-606.
  19. Wang JZ, Li XA, D'Souza WD, Stewart RD. Impact of prolonged fraction delivery times on tumor control: a note of caution for intensity-modulated radiation therapy (IMRT). Int J Radiat Oncol Biol Phys 2003; 57(2): 543-52.
  20. Elkind MM, Sutton H. X-ray damage and recovery in mammalian cells in culture. Nature 1959; 184: 1293-5.
  21. ELKIND MM. The initial part of the survival curve: does it predict the outcome of fractionated radiotherapy? Radiat Res 1988; 114(3): 425-36.
  22. Sugie C, Shibamoto Y, Ito M, Ogino H, Miyamoto A, Fukaya N, et al. Radiobiologic effect of intermittent radiation exposure in murine tumors. Int J Radiat Oncol Biol Phys 2006; 64(2): 619-24.
  23. Jiang L, Xiong XP, Hu CS, Ou ZL, Zhu GP, Ying HM. In vitro and in vivo studies on radiobiological effects of prolonged fraction delivery time in A549 cells. J Radiat Res 2013; 54(2): 230-4.
  24. Shibamoto Y, Ito M, Sugie C, Ogino H, Hara M. Recovery from sublethal damage during intermittent exposures in cultured tumor cells: implications for dose modification in radiosurgery and IMRT. Int J Radiat Oncol Biol Phys 2004; 59(5): 1484-90.
Journal of Isfahan Medical School
Volume 33, Issue 328 - Serial Number 328
January and February 2015
Pages 400-409

Files

History

  • Receive Date: 12 January 2015
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics